Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;11(6):917-919.
doi: 10.21037/hbsn-22-531.

Advances in 3D bioprinting technology for liver regeneration

Changcan Li  1 , Zhuoran Jiang  2 , Huayu Yang  1
Affiliations
Editorial

Advances in 3D bioprinting technology for liver regeneration

Changcan Li et al. Hepatobiliary Surg Nutr. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-531/coif). HY serves as an unpaid editorial board member of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare.

References

    1. Campani C, Nault JC. Systemic treatment of hepatocellular carcinoma: the times they are a-changin'. Hepatobiliary Surg Nutr 2021;10:893-5. 10.21037/hbsn-21-412 - DOI - PMC - PubMed
    1. Zhang T, Merle P, Wang H, et al. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. 10.21037/hbsn-2021-7 - DOI - PMC - PubMed
    1. Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. 10.21037/hbsn.2019.08.08 - DOI - PMC - PubMed
    1. Liu C, Liu Y, Xu XX, et al. Potential effect of matrix stiffness on the enrichment of tumor initiating cells under three-dimensional culture conditions. Exp Cell Res 2015;330:123-34. 10.1016/j.yexcr.2014.07.036 - DOI - PubMed
    1. Hutchinson L, Kirk R. High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol 2011;8:189-90. 10.1038/nrclinonc.2011.34 - DOI - PubMed

Publication types